2023 International HBV Meeting

摘要/摘要 乙肝病毒是一种主要的全球公共卫生威胁，约有2.96亿人慢性感染 全球范围内的感染者和每年超过80万人死亡。慢性乙肝病毒感染是导致 肝硬变和肝细胞癌的发展。尽管预防性乙肝病毒是有效的 疫苗，它对已确定的慢性感染没有影响。因此，非常需要发现新的 治愈慢性乙肝病毒感染并延缓或阻止由此产生的疾病的治疗策略。 一年一度的国际乙肝会议是聚集国际社会的唯一论坛 研究乙肝病毒的感染、持久性、致病机制和药物开发的研究人员 相关的丁型肝炎病毒(HDV)。这届国际乙肝大会自1985年以来每年举行一次。2023年， 这次会议将首次在日本举行，日本是慢性乙肝高度流行的东亚地区， 超过1亿人长期受到影响。 国际乙肝会议的成功不仅取决于老一辈人的贡献 调查人员，但重要的是，也包括来自不同背景的早期职业研究人员。为了方便 青年科学家的参与，我们要求提供资金，以支持早期职业生涯和以下人员的旅行费用- 代表研究人员参加了2023年国际乙肝会议。2023年的会议将提供 科学交流和传播最新研究信息的机会，以发现新的 潜在治愈乙肝病毒和丁型肝炎病毒的策略。预计将有500-600名代表出席2023年的会议。 会议将包括10个科学口头会议，2个海报会议，3个来自外部的专家的全体讲座 谁将带来不同观点的乙肝领域，并由杰出的接受者所做的演讲 每年由大会颁发的乙肝研究奖。对于治愈乙肝病毒和丁型肝炎病毒的目标，这 会议将由乙肝治愈研讨会主持，讨论抗乙肝病毒持久性的潜在机制 SiRNA疗法，以及来自乙肝病毒社区的科学家参与的乙肝病毒社区论坛 公众、媒体、学生和受乙肝病毒影响的人讨论乙肝病毒/HDV及相关疾病。 与以往一样，已作出巨大努力将会议费用降至最低。中国的一大强项 自2005年以来，会议组织一直得到乙肝基金会的支持。为了启用和 促进早期职业研究人员和代表性不足的少数群体调查人员的参与，以最大限度地 由于这次会议的重要性，我们请求美国国立卫生研究院提供支持，以帮助支付他们的旅费 成本。这笔资金将用于确保早期职业研究人员的出席和演示，特别是 来自低收入和中等收入国家的调查人员以及处境不利和代表性不足的少数群体调查员。

ABSTRACT/SUMMARY Hepatitis B virus (HBV) is a major global public health threat with approximately 296 million chronically infected people worldwide and over 800,000 deaths per year. Chronic HBV infection is a leading cause for development of liver cirrhosis and hepatocellular carcinoma. Despite the effectiveness of the prophylactic HBV vaccine, it has no impact on established chronic infections. Consequently, there is a great need to discover new therapeutic strategies to cure chronic HBV infection and slow or stop the resulting disease. The annual International HBV Meeting is the only forum that gathers the international community of researchers who study infection, persistence, pathogenesis, and drug development for HBV and the closely associated hepatitis delta virus (HDV). This International HBV Meeting has been held yearly since 1985. In 2023, this meeting will be held for the first time in Japan, in East Asia where chronic hepatitis B is highly endemic, with over 100 million people chronically affected. Success of the International HBV Meeting relies on the contributions of not only the established investigators, but importantly, also on early career researchers from diverse backgrounds. To facilitate the participation of young scientists, we request funding to support travel expenses for early career and under- represented researchers at the 2023 International HBV Meeting. This 2023 meeting will provide the opportunity for scientific exchange and dissemination of the latest research information to discover new strategies for potentially curing HBV and HDV. An estimated 500-600 delegates will attend the 2023 meeting. The meeting will consist of 10 oral scientific sessions, 2 poster sessions, 3 plenary lectures from experts outside of the HBV field who will bring different perspectives, and a lecture given by the recipient of the Distinguished Award in HBV Research that is awarded annually by the meeting. Toward the goal of curing HBV and HDV, this meeting will be satellited by HBV cure symposium to discuss mechanisms underlying durability of anti-HBV siRNA therapy, and by an HBV community forum where scientists from the HBV community engage with the general public, media, students and those affected by HBV to discuss HBV/HDV and the related diseases. As in the past, great effort has been made to minimize the cost of the meeting. A major strength of the meeting organization being continual support from the Hepatitis B Foundation since 2005. In order to enable and facilitate participation of early career researchers and under-represented minority investigators to maximize the significance of the meeting, we request support from the National Institutes of Health to help defray their travel costs. This funding will be used to ensure attendance and presentation by early career researchers, particularly from low and middle-income countries, as well as disadvantaged and under-represented minority investigators.